Scroll

racecadotril 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
endopeptidase inhibitors	60	81110-73-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: ecadotril acetorphan racecadotril cadotril redotil	A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms. Molecular weight: 385.48 Formula: C21H23NO4S CLOGP: 3.85 LIPINSKI: 0 HAC: 5 HDO: 1 TPSA: 72.47 ALOGS: -5.34 ROTB: 11

Molecule

Description

Molfile Inchi Smiles

Synonyms:

ecadotril
acetorphan
racecadotril
cadotril
redotil

A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.

Molecular weight: 385.48
Formula: C21H23NO4S
CLOGP: 3.85
LIPINSKI: 0
HAC: 5
HDO: 1
TPSA: 72.47
ALOGS: -5.34
ROTB: 11

Drug dosage:

None

ADMET properties:

Property	Value	Reference
MRTD (Maximum Recommended Therapeutic Daily Dose)	11.12 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1993	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Rash maculo-papular	101.95	40.83	37	1665	26604	50576818
Acute kidney injury	91.37	40.83	69	1633	227989	50375433
Cholestasis	74.31	40.83	29	1673	25372	50578050
Agranulocytosis	64.56	40.83	25	1677	21396	50582026
Febrile bone marrow aplasia	62.23	40.83	18	1684	6293	50597129
Aplasia	61.43	40.83	16	1686	3797	50599625
Hepatocellular injury	59.92	40.83	25	1677	25922	50577500
Pancytopenia	48.74	40.83	32	1670	83998	50519424
Pancreatitis acute	48.52	40.83	21	1681	23791	50579631
Housebound	47.70	40.83	8	1694	218	50603204
Granulomatous liver disease	44.03	40.83	9	1693	734	50602688
Thrombocytopenia	43.01	40.83	35	1667	127638	50475784

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Toxic epidermal necrolysis	108.16	40.51	41	1784	18112	29554590
Hepatocellular injury	105.38	40.51	42	1783	21201	29551501
Alveolar lung disease	95.57	40.51	17	1808	352	29572350
Pulmonary interstitial emphysema syndrome	91.60	40.51	17	1808	449	29572253
Diffuse alveolar damage	71.52	40.51	18	1807	2025	29570677
Eosinophilic pneumonia	60.99	40.51	17	1808	2829	29569873
Acute kidney injury	59.62	40.51	77	1748	265190	29307512
Hyperammonaemia	57.37	40.51	19	1806	5644	29567058
Generalised oedema	51.56	40.51	21	1804	11144	29561558
Eosinophilia	46.27	40.51	24	1801	22137	29550565

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hepatocellular injury	154.60	32.32	67	3598	45168	64449899
Acute kidney injury	130.85	32.32	143	3522	449097	64045970
Rash maculo-papular	123.59	32.32	58	3607	46968	64448099
Toxic epidermal necrolysis	120.27	32.32	53	3612	37113	64457954
Alveolar lung disease	103.33	32.32	19	3646	518	64494549
Cholestasis	101.66	32.32	50	3615	44822	64450245
Pulmonary interstitial emphysema syndrome	93.07	32.32	17	3648	446	64494621
Pancytopenia	66.34	32.32	59	3606	143250	64351817
Diffuse alveolar damage	64.74	32.32	18	3647	3217	64491850
Eosinophilia	64.74	32.32	35	3630	38041	64457026
Agranulocytosis	59.09	32.32	33	3632	38196	64456871
Febrile bone marrow aplasia	56.54	32.32	22	3643	11233	64483834
Eosinophilic pneumonia	54.36	32.32	17	3648	4560	64490507
Drug reaction with eosinophilia and systemic symptoms	53.28	32.32	35	3630	54182	64440885
Thrombocytopenia	50.88	32.32	63	3602	223738	64271329
Hyperammonaemia	48.48	32.32	19	3646	9885	64485182
Generalised oedema	46.46	32.32	23	3642	20830	64474237
Aplasia	43.65	32.32	16	3649	6937	64488130
Housebound	43.51	32.32	9	3656	456	64494611
Confusional state	41.80	32.32	62	3603	261082	64233985
Hepatitis	38.96	32.32	27	3638	45555	64449512
Hepatic encephalopathy	37.56	32.32	20	3645	21046	64474021
Pancreatitis acute	35.73	32.32	25	3640	42830	64452237
Angioedema	33.72	32.32	28	3637	61793	64433274

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A07XA04	ALIMENTARY TRACT AND METABOLISM ANTIDIARRHEALS, INTESTINAL ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS OTHER ANTIDIARRHEALS Other antidiarrheals
MeSH PA	D000930	Antidiarrheals
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D005765	Gastrointestinal Agents
MeSH PA	D011480	Protease Inhibitors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Acute diarrhea	indication	409966000

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Neprilysin	Enzyme	P08473	NEP_HUMAN	INHIBITOR	IC50	9	CHEMBL	KEGG DRUG
Endothelin-converting enzyme 1	Enzyme	P42892	ECE1_HUMAN		IC50	8.10	CHEMBL
Angiotensin-converting enzyme	Enzyme	P12821	ACE_HUMAN		IC50	6.50	CHEMBL
Angiotensin-converting enzyme	Enzyme		ACE_RABIT		IC50	6.38	CHEMBL
Neprilysin	Enzyme		NEP_RAT		IC50	8.32	CHEMBL
Neprilysin	Enzyme		NEP_RABIT		IC50	8.40	CHEMBL
Neprilysin	Enzyme		NEP_PIG		IC50	8.21	CHEMBL
Thermolysin	Enzyme		THER_BACTH		IC50	5.02	CHEMBL

External reference:

ID	Source
4025231	VUID
N0000179029	NUI
D08464	KEGG_DRUG
112573-73-6	SECONDARY_CAS_RN
16738	RXNORM
C0050461	UMLSCUI
CHEBI:91508	CHEBI
CHEBI:9568	CHEBI
TIO	PDB_CHEM_ID
CHEMBL2103772	ChEMBL_ID
CHEMBL1516410	ChEMBL_ID
DB11696	DRUGBANK_ID
C049331	MESH_SUPPLEMENTAL_RECORD_UI
107751	PUBCHEM_CID
11654	IUPHAR_LIGAND_ID
5278	IUPHAR_LIGAND_ID
7378	INN_ID
76721-89-6	SECONDARY_CAS_RN
76K53XP4TO	UNII
3132	PUBCHEM_CID
DB08626	DRUGBANK_ID
006079	NDDF
4025231	VANDF
C0039945	UMLSCUI
CHEMBL10247	ChEMBL_ID
6896	INN_ID
699272003	SNOMEDCT_US
714679008	SNOMEDCT_US
785287002	SNOMEDCT_US
D015244	MESH_DESCRIPTOR_UI
B79L7B5X3Z	UNII

Pharmaceutical products:

None